BSX Stock Rises on Positive Data Announcement at the AF Symposium

Zacks01-20 21:35

Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC”) device during...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2504281782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-20 21:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2504281782","market":"us","top_or_hot":-1,"title":"BSX Stock Rises on Positive Data Announcement at the AF Symposium","media":"Zacks","content":"<div>\n<p>Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC”) device during...</p>\n\n<a href=\"https://finance.yahoo.com/news/bsx-stock-rises-positive-data-133500443.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BSX Stock Rises on Positive Data Announcement at the AF Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBSX Stock Rises on Positive Data Announcement at the AF Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-20 21:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bsx-stock-rises-positive-data-133500443.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC”) device during...</p>\n\n<a href=\"https://finance.yahoo.com/news/bsx-stock-rises-positive-data-133500443.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/bsx-stock-rises-positive-data-133500443.html","article_id":"2504281782","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504281782","pubTimestamp":1737380100,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation  system and the WATCHMAN Left Atrial Appendage Closure  device during a late-breaking science session at AF Symposium 2025. The positive findings from the studies provide valuable clinical evidence supporting the company’s ablation and stroke prevention technologies, designed to improve long-term outcomes for patients with atrial fibrillation.Following the announcement, shares of the company moved north 0.5% to $98.66 last Friday.Boston Scientific consistently demonstrates growth within the Cardiovascular segment by bringing advanced technologies like FARAPULSE PFA and WATCHMAN FLX. The company is experiencing rapid and sustained adoption of the transformative FARAPULSE PFA System. At the end of the third quarter of 2024, the company treated over 125,000 patients with FARAPULSE.The concomitant LAAC with the WATCHMAN FLX device following an ablation demonstrated a statisti","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4082":"医疗保健设备","LU0238689110.USD":"贝莱德环球动力股票基金","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","RMD.AU":"Resmed DRC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","RMD":"瑞思迈","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","BSX":"波士顿科学","BK4548":"巴美列捷福持仓","LU0122379950.USD":"贝莱德世界健康科学A2","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","VCYT":"Veracyte Inc","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","OMCL":"Omnicell","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"AF研讨会公布积极数据后BSX股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1,"RMD":1,"BSX":1,"OMCL":1,"RMD.AU":0.9},"content_text":"Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC”) device during a late-breaking science session at AF Symposium 2025. The positive findings from the studies provide valuable clinical evidence supporting the company’s ablation and stroke prevention technologies, designed to improve long-term outcomes for patients with atrial fibrillation.\nLikely Trend of BSX Stock Following the News\nFollowing the announcement, shares of the company moved north 0.5% to $98.66 last Friday.\nBoston Scientific consistently demonstrates growth within the Cardiovascular segment by bringing advanced technologies like FARAPULSE PFA and WATCHMAN FLX. The company is experiencing rapid and sustained adoption of the transformative FARAPULSE PFA System. At the end of the third quarter of 2024, the company treated over 125,000 patients with FARAPULSE.\nAdditionally, the next generation WATCHMAN is strongly capturing the global market. In the third quarter of 2024, WATCHMAN’s organic sales grew 18% year over year. Over 500,000 patients were treated using the device during the quarter. Accordingly, we expect the latest announced favorable study data to bolster investor confidence and maintain the upward momentum in BSX's share price in the upcoming days.\nBSX currently has a market capitalization of $141.41 billion. The company delivered an average earnings surprise of 8.29% for the trailing four quarters.\nAbout ADVANCE AF Clinical Study\nThe ADVANTAGE AF study examined the use of the FARAPULSE PFA System for PVI and posterior wall ablation (PWA) in patients with persistent AF — an irregular or rapid heartbeat that lasts longer than seven days. \nThe study demonstrated that the primary safety endpoint — defined as serious adverse events related to either the use of an ablation catheter or the ablation procedure within seven days of the primary procedure – was met with a 2.3% event rate. The primary effectiveness endpoint — defined as freedom from AF — was met at 63.5%. The symptomatic AF recurrence-free rate was 85.3%. No incidences of stroke, pulmonary vein stenosis, atrio-esophageal fistula or major access complications were observed.\nAbout OPTION Trial Sub-Analysis\nAt the AF session, the company also presented favorable study results for the WATCHMAN FLX device. The study was related to the OPTION clinical trial. It included a sub-analysis of 1,600 patients with atrial fibrillation who underwent device implantation either concomitantly or sequentially. \nThe concomitant LAAC with the WATCHMAN FLX device following an ablation demonstrated a statistically significant 44% reduction in non-procedural bleeding. Sequential LAAC with the WATCHMAN FLX device following an ablation demonstrated a statistically significant 62% reduction in non-procedural bleeding. \nImage Source: Zacks Investment Research\nIndustry Prospects Favor BSX\nPer a report from Future Business Insights, the global cardiovascular devices market size was valued at $61.39 billion in 2023 and is projected to increase $117.68 billion by 2032 at a compound annual growth rate of 7.6% during 2024-2032. The growth of the global cardiovascular market is driven by a significant rise in the prevalence of chronic heart diseases. This provides momentum toward the higher adoption of technologically advanced cardiology devices for diagnosis and treatment.\nAnother Recent Development by BSX\nEarlier this month, Boston Scientific entered into a definitive agreement to acquire Bolt Medical, Inc. — an intravascular lithotripsy (IVL) advanced laser-based platform developer. The acquisition will expand Boston Scientific’s cardiovascular portfolio with Bolt IVL — a complementary and differentiated calcium modification platform. \nBSX’s Price Performance\nIn the past year, BSX’s shares have risen 62.4% compared with the industry’s 11.6% growth.\nBSX’s Zacks Rank and Key Picks\nThe company currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL .\nVeracyte, carrying a Zacks Rank of #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nVCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.\nResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year. \nOmnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504281782"}